Some studies suggested that PHO patients with prostaglandin transporter SLCO2A1 mutations were more likely to develop myelofibrosis [2, 14], which might explain the high incidence of myelofibrosis in PHO patients with GI involvement. Here, SLCO2A1 is linked to myelofibrosis.